Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: ho ptc. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
Chan-Penebre E, Armstrong K, Drew A, Grassian AR, Feldman I, Knutson SK, Kuplast-Barr K, Roche M, Campbell J, Ho P, Copeland RA, Chesworth R, Smith JJ, Keilhack H, Ribich SA. Chan-Penebre E, et al. Mol Cancer Ther. 2017 May;16(5):850-860. doi: 10.1158/1535-7163.MCT-16-0678. Epub 2017 Mar 14. Mol Cancer Ther. 2017. PMID: 28292935
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT. Holen KD, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54. doi: 10.1007/s00280-010-1346-5. Epub 2010 May 12. Cancer Chemother Pharmacol. 2011. PMID: 20461380 Free PMC article. Clinical Trial.
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd. Storniolo AM, et al. J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490651 Clinical Trial.
The value of label recommendations: how to dose lapatinib.
Koch KM, Beelen AP, Ho PT, Roychowdhury DF. Koch KM, et al. J Clin Oncol. 2007 Nov 20;25(33):5331-2; author reply 5334-5. doi: 10.1200/JCO.2007.13.8644. J Clin Oncol. 2007. PMID: 18024883 No abstract available.
Phase I study of perillyl alcohol in patients with refractory malignancies.
Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Murren JR, et al. Cancer Biol Ther. 2002 Mar-Apr;1(2):130-5. doi: 10.4161/cbt.57. Cancer Biol Ther. 2002. PMID: 12170772 Free article. Clinical Trial.